Mobile

A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003860-47

A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid only, in adult and adolescent patients with seasonal allergic asthma and comorbid sea-sonal allergic rhinoconjunctivitis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that Depigoid as combination therapy with Omalizumab, compared to Depigoid monotherapy, has superior efficacy as for daily symptom load in adult and adolescent patients sensitized against grass pollen allergens with (not adequately controlled and therefore symptomatic) seasonal allergic asthma and comorbidity with seasonal allergic rhinoconjunctivitis.

Critère d'inclusion

  • Asthma extrinsic

Liens